Simply sign up for a free PR Canna Zine membership, and post your press release. Its as easy as that!
From that point forth your press release will be published alongside the daily CannaZine press output, which is indexed by Google News many times a day.
GW Pharmaceuticals Plc announced today via Reuters, that a study of its cannabis-based pain killer Sativex has shown long-term efficacy in the treatment of neuropathic pain due to multiple sclerosis.
It is the first time that the long-term effectiveness of the drug had been demonstrated in a so-called placebo-controlled study, where it is tested against a dummy drug.
The news is also significant for the company because it bolsters hopes that it might gain approval for the drug as a treatment for spasticity associated with multiple sclerosis, because the trial is very similar to a late-stage trial that has been running at the request of regulators.
Stephen Wright, GW's R&D Director, said in a statement: "It is encouraging to note that if the difference between Sativex and placebo achieved in the results today are replicated in the ongoing Phase III MS spasticity study, this Phase III study will meet its objectives."
Whilst we understand the importance of getting drugs ready for public market isn't it about time someone asked what the delay is?
Or is it the fact its a cannabis based medicine, which makes it require even more stringent testing initially.
Clearly this could be a valid theory as it has also been announced today that another Multiple Sclerosis drug, Tysabri, has been placed under FDA investigation in America due to possible links with skin cancer.
The FDA said it is investigating a potential link to skin melanoma, a dangerous cancer. Doctors in Boston had reported two cases of melanoma in Tysabri patients in a letter to the New England Journal of Medicine in February. Tysabri suppresses the immune system, and it has also been linked to a rare kind of brain infection that is often fatal. Manufacturer Biogen Idec Inc. said it does not believe there is an increased risk of melanoma.
So while tens of thousands of MS patients around the world await the roll-out of an inherently safe cannabis extract, delayed because it might make people happy (read: stoned), one of the options available is a drug which is under investigation as a possible skin cancer cause?
With friends like that running our nation..who needs enemies?
